Citation

BibTex format

@article{Schneider:2019:10.1016/j.stem.2019.01.013,
author = {Schneider, M and Fiedler, L and Chapman, K and Xie, M and Maifosie, E and Jenkins, M and Golforoush, P and Bellahcene, M and Noseda, M and Faust, D and Jarvis, A and Newton, G and Paiva, MA and Harada, M and Stuckey, DJ and Song, W and Habib, J and Narasimham, P and Aqil, R and Sanmugalingam, D and Yan, R and Pavanello, L and Sano, M and Wang, SC and Sampson, RD and Kanayaganam, S and Taffet, GE and Michael, LH and Entman, ML and Tan, T and Harding, S and Low, CMR and Tralau-Stewart, C and Perrior, T and Schneider, MD},
doi = {10.1016/j.stem.2019.01.013},
journal = {Cell Stem Cell},
pages = {579--591.e12},
title = {MAP4K4 inhibition promotes survival of human stem cell derived cardiomyocyte and reduces infarct size in vivo},
url = {http://dx.doi.org/10.1016/j.stem.2019.01.013},
volume = {24},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Heart disease is a paramount cause of global death and disability. Although cardiomyocyte death plays a causal role and its suppression would be logical, no clinical counter-measures target the responsible intracellular pathways. Therapeutic progress has been hampered by lack of preclinical human validation. Mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K4) is activated in failing human hearts and relevant rodent models. Using human induced-pluripotent-stem-cell-derived cardiomyocytes (hiPSC-CMs) and MAP4K4 gene silencing, we demonstrate that death induced by oxidative stress requires MAP4K4. Consequently, we devised a small-molecule inhibitor, DMX-5804, that rescues cell survival, mitochondrial function, and calcium cycling in hiPSC-CMs. As proof of principle that drug discovery in hiPSC-CMs may predict efficacy in vivo, DMX-5804 reduces ischemia-reperfusion injury in mice by more than 50%. We implicate MAP4K4 as a well-posed target toward suppressing human cardiac cell death and highlight the utility of hiPSC-CMs in drug discovery to enhance cardiomyocyte survival.
AU  - Schneider,M
AU  - Fiedler,L
AU  - Chapman,K
AU  - Xie,M
AU  - Maifosie,E
AU  - Jenkins,M
AU  - Golforoush,P
AU  - Bellahcene,M
AU  - Noseda,M
AU  - Faust,D
AU  - Jarvis,A
AU  - Newton,G
AU  - Paiva,MA
AU  - Harada,M
AU  - Stuckey,DJ
AU  - Song,W
AU  - Habib,J
AU  - Narasimham,P
AU  - Aqil,R
AU  - Sanmugalingam,D
AU  - Yan,R
AU  - Pavanello,L
AU  - Sano,M
AU  - Wang,SC
AU  - Sampson,RD
AU  - Kanayaganam,S
AU  - Taffet,GE
AU  - Michael,LH
AU  - Entman,ML
AU  - Tan,T
AU  - Harding,S
AU  - Low,CMR
AU  - Tralau-Stewart,C
AU  - Perrior,T
AU  - Schneider,MD
DO  - 10.1016/j.stem.2019.01.013
EP  - 591
PY  - 2019///
SN  - 1875-9777
SP  - 579
TI  - MAP4K4 inhibition promotes survival of human stem cell derived cardiomyocyte and reduces infarct size in vivo
T2  - Cell Stem Cell
UR  - http://dx.doi.org/10.1016/j.stem.2019.01.013
UR  - https://www.sciencedirect.com/science/article/pii/S193459091930013X?via%3Dihub
UR  - http://hdl.handle.net/10044/1/67491
VL  - 24
ER  -
Download